Cambridge Protein Arrays

Executive Summary

Cambridge Protein Arrays (CPA) is a UK-based biotechnology company that provides the HuProt™ platform, the world's most comprehensive high-density human proteome microarray, enabling researchers to screen protein interactions on a proteome-wide scale. Founded in 2013, the company's dual business model combines direct sales of its microarrays with custom contract screening services for both academic and pharmaceutical clients. As the demand for proteomics tools grows, CPA is strategically positioned to support early-stage drug discovery, biomarker identification, and autoimmune disease profiling. The company's proprietary technology offers a key differentiator in the competitive proteomics landscape, allowing end-users to interrogate thousands of full-length proteins simultaneously with high reproducibility. Although the firm remains private and has not disclosed funding rounds or revenue figures, its established commercial products and service offerings suggest a steady market presence. The increasing adoption of proteomic approaches in personalized medicine and diagnostics presents a tangible growth opportunity for CPA, particularly if it can secure partnerships with larger diagnostic firms or expand into clinical applications. The company's focus on high-quality, full-length protein arrays addresses a critical gap in the research tool market, and its continued innovation in array content and throughput will be essential for maintaining its competitive edge.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation HuProt Array with Expanded Protein Coverage70% success
• Q1 2027Strategic Diagnostic Partnership for Autoimmune Disease Biomarker Panel50% success
• H2 2026Series A or B Funding Round to Scale Manufacturing and Commercial Operations60% success